NL-OMON46573已完成不适用
A double-blind, placebo-controlled, randomized, single and multiple ascending dose study (including food effect, pH effect, and Japanese bridging Study) of the safety, pharmacokinetics, and exploratory pharmacodynamics of oral BMS-986278 administration in healthy participants - BMS-986278 SAD MAD FE pH Japanese study
Bristol-Myers Squibb Research and Development0 个研究点目标入组 62 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- healthy volunteers
- •- 21-65 yrs, inclusive, at screening
- •- BMI: 18.0-30.0 kg/m2, inclusive, at screening
- •- body weight: between 55 and 105 kg, inclusive, at screening
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study. Donation or loss of more than 100 mL of blood within 2 months prior to (the first) drug administration. Donation or loss of more than 1.5 L of blood (for male participants)/more than 1.0 L of blood (for female participants) in the 10 months prior to (the first) drug administration in the current study.
研究者
相似试验
已完成
不适用
A double-blind, placebo-controlled, randomized, single and multiple ascending dose study of the safety and tolerability, and pharmacokinetics (including food effect, pH effect and Japanese bridging study) of BMS-986337 following oral administration in healthy participantsidiopathic pulmonary fibrosisNL-OMON49565Bristol-Myers Squibb Research and Development78
招募中
1 期
To evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TX000045 (single ascending dose) in Healthy VolunteersCardiovascularCardiovascular - Other cardiovascular diseasesRespiratory - Other respiratory disorders / diseasesACTRN12623001054606Tectonic Therapeutic48
进行中（未招募）
1 期
A Phase II study with KH176 in patients with mitochondrial diseaseInherited mitochondrial disease, including MELAS (mitochondrial Encephalopathy Lactic Acidosis and Stroke like episodes) and MIDD (Maternally Inherited Diabetes and Deafness)EUCTR2016-001696-79-NLKhondrion BV
招募中
2 期
A double-blind, randomized, placebo-controlled, single-center, two-way cross-over study with KH176 in patients with the mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation and clinical signs of mitochondrial diseaseMitochondriale aandoeningendysfunctional energy metabolismOxidative Phosphorylation DisordersNL-OMON42839Khondrion B.V.20
进行中（未招募）
1 期
A randomized, placebo-controlled, double-blind, six-arm, dose escalation, multi-center study to evaluate the efficacy and safety of SLV306: 150, 300, 600 mg once daily, 150-300 mg twice daily and amlodipine 5-10 mg once daily in subjects with hypertension.HypertensionEUCTR2004-000305-21-SKSolvay Pharmaceuticals522